Empire Life Investments Inc. Sells 705 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Empire Life Investments Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,080 shares of the biopharmaceutical company's stock after selling 705 shares during the quarter. Empire Life Investments Inc.'s holdings in Regeneron Pharmaceuticals were worth $2,906,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. ABC Arbitrage SA acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $1,510,000. Klingenstein Fields & Co. LP grew its position in shares of Regeneron Pharmaceuticals by 1,083.7% in the 4th quarter. Klingenstein Fields & Co. LP now owns 6,806 shares of the biopharmaceutical company's stock valued at $4,848,000 after buying an additional 6,231 shares during the last quarter. Banque Pictet & Cie SA acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $4,496,000. V Square Quantitative Management LLC raised its position in shares of Regeneron Pharmaceuticals by 11.9% during the fourth quarter. V Square Quantitative Management LLC now owns 1,489 shares of the biopharmaceutical company's stock worth $1,061,000 after acquiring an additional 158 shares during the last quarter. Finally, Vontobel Holding Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 56.1% in the fourth quarter. Vontobel Holding Ltd. now owns 6,458 shares of the biopharmaceutical company's stock worth $4,600,000 after acquiring an additional 2,322 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $5.66 during mid-day trading on Wednesday, hitting $685.66. 638,281 shares of the stock were exchanged, compared to its average volume of 938,896. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $74.96 billion, a P/E ratio of 17.91, a P/E/G ratio of 2.26 and a beta of 0.08. The company has a 50-day simple moving average of $700.92 and a 200 day simple moving average of $887.66. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $11.86 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.51%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Citigroup decreased their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Bernstein Bank decreased their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.